Treatment of pulmonary hypertension with carbonic anhydrase inhibitors
Inventors
Najarian, Thomas • Tam, Peter Y. • Wilson, Leland F. • Peterson, Craig
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-8536138-B2
Publication Date
2013-09-17
Expiration Date
Abstract
This disclosure relates generally to methods and pharmaceutical compositions useful in treating pulmonary hypertension. In one embodiment, for example, the disclosure provides a method for treating pulmonary hypertension comprising administering a therapeutically effective dose of a carbonic anhydrase inhibitor to a patient in need of treatment. The disclosure finds utility in the fields of medicine and pharmacology.
Core Innovation
The disclosed invention provides a method for treating secondary pulmonary hypertension in a patient by administering a therapeutically effective dose of topiramate together with a therapeutically effective dose of a Type V phosphodiesterase inhibitor. The document emphasizes combined administration of topiramate and a Type V phosphodiesterase inhibitor as a treatment regimen for secondary pulmonary hypertension.
The invention further describes that, in addition to treating secondary pulmonary hypertension, topiramate can additionally treat the cause of the secondary pulmonary hypertension. The Type V phosphodiesterase inhibitor is selected from avanafil, sildenafil, tadalafil, zaprinast, dipyridamole, vardenafil, or an acid addition salt thereof.
A further aspect of the invention characterizes topiramate administration as a gradually increased daily dose over an extended time period to reach a final daily dosage suitable for continued maintenance therapy. The final daily dosage is in the range of about 10 mg to 400 mg, together with continued co-administration of a Type V phosphodiesterase inhibitor.
Claims Coverage
The partial content identifies two independent claims covering combination therapy of topiramate with a Type V phosphodiesterase inhibitor for secondary pulmonary hypertension and an extended titration regimen for topiramate in combination with a Type V phosphodiesterase inhibitor.
Topiramate plus Type V phosphodiesterase inhibitor for treating secondary pulmonary hypertension
Administering a therapeutically effective dose of topiramate and a therapeutically effective dose of a Type V phosphodiesterase inhibitor to a patient to treat secondary pulmonary hypertension.
Gradual titration of topiramate with Type V phosphodiesterase inhibitor maintenance therapy
Administering to the patient a daily dose of topiramate that is gradually increased over an extended time period from an initial daily dosage up to a final daily dosage suitable for continued maintenance therapy, wherein the final daily dosage is about 10 mg to 400 mg, together with a Type V phosphodiesterase inhibitor.
Across the independent claims, the central inventive contribution is treating secondary pulmonary hypertension by combining topiramate with a Type V phosphodiesterase inhibitor, with additional coverage for a gradually increased topiramate daily dose leading to a maintenance dose range and continued co-administration of the Type V phosphodiesterase inhibitor.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Treating secondary pulmonary hypertension, including secondary pulmonary hypertension associated with sleep apnea and chronic obstructive pulmonary disease.
Interested in licensing this patent?